Clinical trial
A Phase II Study of BIBW 2992 Administration in Patients With Hormone Refractory Metastatic Breast Cancer
NCT00708214 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of BIBW 2992 Administration in Patients With Hormone Refractory Metastatic Breast Cancer
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- Not reported
- Enrollment
- 28 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.